PCI ExTract - Clinical Trial Results The International Leader in PCI提取物的临床试验结果的国际领先.pptVIP

下载本文档

1
0
约8.86千字
约 23页
2018-04-17 发布于江西
举报
版权申诉

PCI ExTract - Clinical Trial Results The International Leader in PCI提取物的临床试验结果的国际领先.ppt

1、本文档共23页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

PCI ExTract - Clinical Trial Results The International Leader in PCI提取物的临床试验结果的国际领先.ppt

PCI in Patients Receiving Enoxaparin or UFH Following Fibrinolytic Therapy for STEMI:PCI ExTRACT-TIMI 25 Disclosure Background: Main Results ExTRACT-TIMI 25 Objective Baseline Characteristics PCI Cohort N = 4,676 Medications During Hospitalization PCI Cohort N = 4,676 PCI Cohort: Primary EndpointDeath or Nonfatal MI by 30 days PCI Cohort: Safety PCI Cohort: Death or Nonfatal reMI - Major Subgroups PCI Cohort:Nonfatal Recurrent MI by 30 days Incidence and Relative Timing of PCI Relative Timing of PCI: Urgent vs Non-Urgent PCI Outcomes by 30 Days in Patients Undergoing PCI on Blinded Study Drug PCI Performed on Blinded Study Drug Two scenarios in which a patient underwent PCI on study drug: 1) Blinded study drug never discontinued and PCI performed on blinded study drug 2) Blinded study drug discontinued prior to PCI and then resumed at time of PCI Death or Nonfatal MI by 30 days Among PCI Patients in Whom Study Drug Was Not Discontinued (n=1501) Conclusion Conclusion (cont.) ENOX was associated with ↓ risk of death or reMI both among patients in whom antithrombin was continued as well as discontinued prior to PCI. ENOX associated with both delayed onset and ↓ occurrence of reMI, both of which may expand window of opportunity to perform PCI following fibrinolytic administration. Back Up Slides We are pleased to report that a detailed presentation of our primary results can be found in a paper that is now posted on the New England Journal of Medicine website . Also, The slides shown today and a full list of the trial participants are now posted on the TIMI website. Thank you very much for your attention. * C. Michael Gibson, Sabina A. Murphy, David A. Morrow, Carolyn H. McCabe, Dietrich C. Gulba, Gilles Montalescot, Servet Cetin, Oscar H. Kracoff, Basil S. Lewis, Nathan Roguin, Elliott M. Antman,Eugene Braunwald, for the ExTRACT-TIMI 25 Investigators Accumetrics, Inc. Amgen, Inc. AstraZeneca Pharmaceuticals LP Baxter Bayer H